According to the New York Times, Valeant Pharmaceuticals has issued a statement following criticism from Hillary Clinton’s presidential campaign about it raising the cost of the drug D.H. E., noting that there was a generic version of the drug available and that it had less than 1% of the market share on D.H.E, which costs $14,000 for 10 vials, $11,000 more than it cost in June 2014. “Whenever the sales volume of a drug declines, manufacturers must consider pricing adjustments to keep production of the drug viable,” the company said. (New York Times)
The drug had previously received two breakthrough therapy designations from the FDA to treat chronic HCV GT1 infection in end-stage renal disease patients on hemodialysis, as well as for the treatment of chronic HCV GT4 infection.
The Task Force found that patients who were identified through depression screening and went on to be treated — with antidepressant medication, psychotherapy or both — showed improvement in depression symptoms.
The ranking was created by creating overall scores based on the ratio of positive to negative medication reviews online by using TreatoVoice, which identifies and ranks patient experience base on their online postings.
Last year, many new multimedia features were added to the redesigned website, which includes a newsfeed, commentary, infographics, animations, video clips, health calculators and trackers, quizzes, as well as a drug interaction checker, pill identifier, and guide to pronunciation of medical terms.